GE

281.8

+0.04%↑

RTX

155.99

-1.13%↓

CAT

431.07

-0.1%↓

BA

216.27

-1.87%↓

GEV.US

625.84

-1.5%↓

GE

281.8

+0.04%↑

RTX

155.99

-1.13%↓

CAT

431.07

-0.1%↓

BA

216.27

-1.87%↓

GEV.US

625.84

-1.5%↓

GE

281.8

+0.04%↑

RTX

155.99

-1.13%↓

CAT

431.07

-0.1%↓

BA

216.27

-1.87%↓

GEV.US

625.84

-1.5%↓

GE

281.8

+0.04%↑

RTX

155.99

-1.13%↓

CAT

431.07

-0.1%↓

BA

216.27

-1.87%↓

GEV.US

625.84

-1.5%↓

GE

281.8

+0.04%↑

RTX

155.99

-1.13%↓

CAT

431.07

-0.1%↓

BA

216.27

-1.87%↓

GEV.US

625.84

-1.5%↓

Search

Ocugen Inc

Suletud

1.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.05

Max

1.06

Põhinäitajad

By Trading Economics

Sissetulek

611K

-15M

Müük

-108K

1.4M

Kasumimarginaal

-1,073.489

Töötajad

95

EBITDA

724K

-13M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+491.59% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. nov 2025

Turustatistika

By TradingEconomics

Turukapital

3.4M

322M

Eelmine avamishind

1.06

Eelmine sulgemishind

1.06

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Ocugen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. sept 2025, 22:41 UTC

Suurimad hinnamuutused turgudel

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12. sept 2025, 16:04 UTC

Suurimad hinnamuutused turgudel

Upexi Shares Climb on Solana Gains

12. sept 2025, 15:03 UTC

Suurimad hinnamuutused turgudel

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12. sept 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

12. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. sept 2025, 20:09 UTC

Tulu

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12. sept 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. sept 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. sept 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12. sept 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12. sept 2025, 18:38 UTC

Market Talk
Tulu

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12. sept 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12. sept 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12. sept 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12. sept 2025, 16:22 UTC

Tulu

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. sept 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12. sept 2025, 16:11 UTC

Tulu

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12. sept 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12. sept 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12. sept 2025, 15:07 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. sept 2025, 14:34 UTC

Market Talk

Russia Sanctions Put Bid Back in Oil -- Market Talk

12. sept 2025, 14:10 UTC

Market Talk

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12. sept 2025, 13:58 UTC

Market Talk

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12. sept 2025, 13:58 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12. sept 2025, 13:57 UTC

Tulu

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12. sept 2025, 13:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. sept 2025, 13:56 UTC

Market Talk

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12. sept 2025, 13:54 UTC

Market Talk

U.S. Natural Gas Recovers Ground -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ocugen Inc Prognoos

Hinnasiht

By TipRanks

491.59% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD  491.59%

Kõrge 8 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Ocugen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6818 / 0.74Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat